• KOLs Community
    • Extracellular
    • Extracellular Vesicles
    • Fred H Hochberg
    • Fred H Hochberg

      Fred H Hochberg

      Massachusetts General Hospital, Boston, Massachusetts, USA | Scintillon Institute, La Jolla, CA, United States. | University of California, San Diego, Department of ...



      KOL Resume for Fred H Hochberg


      Massachusetts General Hospital, Boston, Massachusetts, USA


      Scintillon Institute, La Jolla, CA, United States.


      University of California, San Diego, Department of Neurosurgery, La Jolla, CA, USA


      Center for Theoretical and Applied Neuro-Oncology, University of California, San Diego, CA, USA.

      Department of Neurosurgery, University of California, San Diego, CA, USA


      Department of Otolaryngology, Eaton Peabody Laboratories, Massachusetts Eye and Ear, Boston, Massachusetts (V.Y.R.S., T.F., S.D., L.D.L., K.M.S.); Department of Otology and Laryngology, Harvard Medical School, Boston, Massachusetts (V.Y.R.S., T.F., L.D.L., K.M.S.); Health Science Program and Department of Otolaryngology, University of Brasilia, Brasília, Distrito Federal, Brazil (V.Y.R.S., C.A.P.C.O., F.B.); University of Amsterdam, Amsterdam, the Netherlands (N.A.A.); Department of Neurology and Radiology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Charlestown, Massachusetts (N.A.A., S.S., X.O.B.); Harvard-MIT Program in Speech and Hearing Bioscience and Technology, Boston, Massachusetts (S.D., K.M.S); Department of Neurosurgery, University of California at San Diego, San Diego, California (F.H.H.)

      Neurology Service, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School, Boston, Massachusetts, United States of America.

      18 Clovelly Road, 02467, Chestnut Hill, MA, USA


      Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA


      Departments of Neurology and Radiology, Massachusetts General Hospital, and Program in Neuroscience, Harvard Medical School, Boston, MA, USA

      Massachusetts General Hospital Division of Neuro‐Oncology Boston Massachusetts


      Harvard Medical School, Boston, Massachusetts; Massachusetts General Hospital (MGH), Boston, Massachusetts.

      Neuroscience Center at Massachusetts General Hospital, Charlestown, MA 02129.

      Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA

      Neuro-Oncology, Massachusetts General Hospital, Boston, MA


      Department of Neurology, Neurosurgery and Radiology, Massachusetts General Hospital and Program in Neuroscience, Harvard Medical School, Boston, MA 02114, USA

      Massachusetts General Hospital, Boston, MA


      MGH Cancer Center, Boston, Massachusetts


      A.A. Martinos Center for Biomedical Imaging, Division of Health Sciences and Technology, Massachusetts Institute of Technology and Massachusetts General Hospital, Charlestown, MA

      From the Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center

      and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD.

      Vascular Biology Program, Children's Hospital Boston, Harvard Medical School, Boston


      Massachusetts General Hospital, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA; Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, Boston, MA; Memorial Sloan-Kettering Cancer Center, New York, NY; Dartmouth-Hitchcock Medical Center, Lebanon, NH; Sigma-Tau Research, Inc., Gaithersburg, MD; Sigma-Tau Industrie Farmaceutiche Reiunite S.p.A., Pomezia, Italy; Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA; Massachusetts General Hospital, Boston, MA


      EP Hochberg is a Medical Oncologist and Director of Clinical Lymphoma Research, N Raje is a Hematologist and Oncologist, M Ulrickson is a Resident in Internal Medicine and FH Hochberg is an Attending Neurologist (Neuro-oncology) at the Massachusetts General Hospital, Boston, MA, USA.

      From the Dana-Farber Cancer Institute

      Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC

      and the Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC

      Beth Israel Deaconess Medical Center, Boston, MA


      FH Hochberg is Attending Neurologist (neuro-oncology), and EP Hochberg is a medical oncologist and Director of Clinical Lymphoma Research, at the Massachusetts General Hospital Boston, MA 02114, USA

      and the Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

      Director, Section of Movement Disorders, Rush University Medical Center, Chicago, Illinois

      Merck KGaA, Darmstadt, Germany

      Professor, Department of Neurological Sciences


      Brain Tumor/Oncology Center, Massachusetts General Hospital, 100 Blossom Street, COX 315, 02114-2617, Boston, MA, USA

      Harvard Medical School, Boston, MA; Sigma Tau Research, Inc., Gaithersburg, MD; Sigma-Tau S.p.A Industrie Farmaceutiche Riunite, Pomezia, Italy; Dana-Farber Cancer Institute, Boston, MA

      Department of Neurology, Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts.


      Brain Tumor Center, Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts


      Department of Neurology, Massachusetts General Hospital East, Charlestown, USA

      Brigham and Women's Hospital, Boston, MA; Dana Farber Cancer Institute, Boston, MA; Massachussetts General Hospital, Boston, MA

      New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium, Baltimore, Maryland


      Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

      From the Massachusetts General Hospital, Boston, MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; University of Alabama at Birmingham, Birmingham, AL; University of Pennsylvania, Philadelphia, PA; University of Texas at San Antonio, San Antonio, TX.


      For complete author affiliations, see the Appendix at the end of the article.

      Neuromedicine Service, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, 02129, USA


      Massachusetts General Hospital, Boston, USA, e-mail: US


      Neurology, and

      Massachusetts General Hospital, Boston 02114, USA.



      Fred H Hochberg: Influence Statistics

      Sample of concepts for which Fred H Hochberg is among the top experts in the world.
      Concept World rank
      reproducible sustained releases #1
      externally maintained ontologies #1
      progressive disease initiation #1
      axonal preservation biopsy #1
      videoconferencing features #1
      495 weeks #1
      glioma progression combinations #1
      localized intracerebral tumor #1
      cbdca lcec #1
      cd8 delta #1
      intracarotid bcnu infusion #1
      determination reductive lcec #1
      response 32 months #1
      rtbc asct #1
      longest responders #1
      intraocular lymphoma treatment #1
      percentage systemic disease #1
      chiasm waldenström #1
      mechanism visual failure #1
      nervous hodgkin #1
      intravenous mtx #1
      diminished contrast enhancement #1
      survival degree #1
      illness glioma humans #1
      nhl tbc #1
      intraarterial bcnu treatment #1
      neurooncologic applications exosomes #1
      primary malignancy methods #1
      highgrade enhancing gliomas #1
      cns nhl asct #1
      radiation pcnsl patients #1
      irradiation cisplatin infusions #1
      dexamethasoneinduced weight loss #1
      mtx toxicity response #1
      evs 150 nm #1
      years pcnsl #1
      bingneel syndrome waldenström #1
      mirna diagnostic biomarker #1
      cancer patients country #1
      472 infinity #1
      nhls threefold rise #1
      drugs chemical names #1
      sspe instance #1
      lumbar csf sensitivity #1
      171 infusions #1
      grade 2 lesions #1
      5 adenoviral injection #1
      mouse icam1 expression #1
      neurological syndromes ischemia #1
      lfa1β icam1 #1


      Prominent publications by Fred H Hochberg

      KOL-Index: 15742

      BACKGROUND: High-dose thiotepa, busulfan, and cyclophosphamide (TBC) with autologous stem cell transplantation (ASCT) has been used in patients with central nervous system (CNS) involvement by non-Hodgkin lymphoma (NHL). Despite limited penetration into the CNS, rituximab is active in primary CNS NHL. Therefore, high-dose rituximab was combined with TBC for ASCT in patients with CNS NHL.

      METHODS: A single-arm phase 2 trial using high-dose rituximab with cytarabine for stem cell ...

      Known for Cell Transplantation | Hodgkin Lymphoma | Asct Patients | Central Nervous | Autologous Stem
      KOL-Index: 14322

      Primary central nervous system non-Hodgkin lymphoma (PCNSL) carries a poor prognosis and, although it responds to chemotherapy, fewer than 20% of patients are long-term disease-free survivors. Secondary CNS non-Hodgkin lymphoma (SCNSL) has an even worse prognosis with a median survival of only months and very few reported long-term survivors. For both of these groups of patients, there has been interest in using high-dose chemotherapy with autologous stem cell transplantation (ASCT) ...

      Known for Hodgkin Lymphoma | Cns Involvement | Stem Cell | Tbc Asct | Thiotepa Busulfan
      KOL-Index: 14041

      RATIONALE AND OBJECTIVES: Distinguishing recurrent glial tumor from radiation necrosis can be challenging. The purpose of this pilot study was to preliminarily compare unenhanced arterial spin-labeled (ASL) imaging, dynamic susceptibility contrast-enhanced cerebral blood volume (DSCE-CBV) magnetic resonance imaging, and positron emission tomographic (PET) imaging in distinguishing predominant glioma recurrence or progression from predominant radiation necrosis in postoperative patients ...

      Known for Radiation Necrosis | Glioma Recurrence | Asl Imaging | Sensitivity Specificity | Susceptibility Contrast
      KOL-Index: 12344

      OBJECT: In this study the authors assessed the early changes in brain tumor physiology associated with glucocorticoid administration. Glucocorticoids have a dramatic effect on symptoms in patients with brain tumors over a time scale ranging from minutes to a few hours. Previous studies have indicated that glucocorticoids may act either by decreasing cerebral blood volume (CBV) or blood-tumor barrier (BTB) permeability and thereby the degree of vasogenic edema.

      METHODS: Using magnetic ...

      Known for Brain Tumors | Magnetic Resonance | Blood Volume | Barrier Permeability | Dexamethasone Patients
      KOL-Index: 12191

      BACKGROUND AND PURPOSE: The MR imaging characteristics of oligodendrogliomas and astrocytomas on spin-echo (SE), echo-planar relative cerebral blood volume (rCBV) maps, to our knowledge, have not previously been emphasized. We compared the specificity of SE rCBV mapping with that of conventional, contrast material-enhanced MR imaging in differentiating high- from low-grade glial tumors and in predicting survival of patients with these lesions.

      METHODS: Thirty consecutive adult patients ...

      Known for Glial Tumor | Contrast Enhancement | Grade Oligodendrogliomas | Ncbv Values | Flow Sensitivity
      KOL-Index: 11666

      The authors provided procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy to 32 patients whose tumors contained varying mixtures of oligodendroglial and astrocytic cells. Twenty-five patients had oligodendroglioma-astrocytoma (oligoastrocytoma) with a histological Grade of III (19 patients) or IV (six patients); seven had anaplastic oligodendroglioma. The PCV therapy was administered every 6 weeks for a total of at least 124 cycles. The median duration of follow-up review ...

      Known for Grade Iii | Procarbazine Lomustine | Pcv Therapy | Progression Patients | Anaplastic Oligodendroglioma
      KOL-Index: 11470

      PURPOSE: One third of women with advanced human epidermal growth factor receptor 2 (HER-2)-positive breast cancer develop brain metastases; a subset progress in the CNS despite standard approaches. Medical therapies for refractory brain metastases are neither well-studied nor established. We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2-positive brain metastases.


      Known for Brain Metastases | Positive Breast | Growth Factor | Patients Lapatinib | Objective Response
      KOL-Index: 11252

      PURPOSE: Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma.

      METHODS: Cediranib, an oral pan-VEGF receptor tyrosine kinase inhibitor, was administered (45 mg/d) until progression or unacceptable toxicity to patients with recurrent glioblastoma. The primary end point was the proportion of patients alive and progression free at 6 ...

      Known for Recurrent Glioblastoma | Growth Factor | Cediranib Patients | Vascular Endothelial | Radiographic Response
      KOL-Index: 11048

      Malignant oligodendrogliomas have been shown to be responsive to chemotherapy. The authors administered systemic chemotherapy to seven patients with oligodendroglioma or anaplastic oligodendroglioma, and to 14 with mixed oligodendroglioma-astrocytoma. Fourteen patients underwent chemotherapy before and seven after irradiation. The PCV (procarbazine, methyl-1-(2-chloroethyl)-1-nitrosourea (CCNU), and vincristine) chemotherapy was administered every 6 weeks (42-day cycles) for two to five ...

      Known for Pcv Chemotherapy | Patients Anaplastic Oligodendroglioma | Tumor Growth | Therapy Authors | Vincristine 14
      KOL-Index: 10627

      Background: RNAs within extracellular vesicles (EVs) have potential as diagnostic biomarkers for patients with cancer and are identified in a variety of biofluids. Glioblastomas (GBMs) release EVs containing RNA into cerebrospinal fluid (CSF). Here we describe a multi-institutional study of RNA extracted from CSF-derived EVs of GBM patients to detect the presence of tumor-associated amplifications and mutations in epidermal growth factor receptor (EGFR).

      Methods: CSF and matching tumor ...

      Known for Glioblastoma Patients | Extracellular Vesicles | Egfrviii Mutation | Derived Evs | Egfr Amplification
      KOL-Index: 10626

      The Response Evaluation Criteria in Solid Tumors, or RECIST criteria (one-dimensional [1D] measurement), are widely used to measure response in tumors, but there are few studies evaluating these criteria in brain tumors. We compared linear and volumetric measurements in adult high-grade supratentorial enhancing gliomas to determine the agreement between measurements, in defining responses and in their subsequent relation to survival. We hypothesized that the 1D RECIST criteria maybe ...

      Known for Tumor Response | Grade Gliomas | Volumetric Criteria | Mri Scans | Adult Brain
      KOL-Index: 10559

      PURPOSE: This study evaluates the efficacy and toxicity of whole-brain radiation therapy (WBRT) as salvage therapy for immunocompetent patients who failed initial high-dose methotrexate for primary CNS lymphoma (PCNSL).

      PATIENTS AND METHODS: The study cohort included 27 consecutive patients who failed initial high-dose methotrexate and then received salvage WBRT (median dose, 36 Gy). Actuarial survival was measured from the initiation of radiotherapy.

      RESULTS: Ten patients (37%) achieved ...

      Known for Immunocompetent Patients | Primary Cns Lymphoma | Brain Radiation | Late Neurotoxicity | Wbrt Pcnsl
      KOL-Index: 10517

      Glioblastoma cells secrete extra-cellular vesicles (EVs) containing microRNAs (miRNAs). Analysis of these EV miRNAs in the bio-fluids of afflicted patients represents a potential platform for biomarker development. However, the analytic algorithm for quantitative assessment of EV miRNA remains under-developed. Here, we demonstrate that the reference transcripts commonly used for quantitative PCR (including GAPDH, 18S rRNA, and hsa-miR-103) were unreliable for assessing EV miRNA. In this ...

      Known for Cerebrospinal Fluid | Biomarker Development | Extracellular Vesicles | Tumor Cell | Evs Csf
      KOL-Index: 10152

      BACKGROUND: Primary central nervous system non-Hodgkin's lymphoma (NHL-CNS) is an enigmatic disease of uncertain origin. At the Massachusetts General Hospital, 104 patients with NHL-CNS were seen from 1958 through 1989. An impression of changes in the frequency of diagnosis, character of the tumors, and therapy for this disease prompted this study of the pathologic features, clinical data, and natural history of this tumor in these 104 patients.

      METHODS: Histologic slides (neurosurgical ...

      Known for Primary Central Nervous | Clinical Correlations | Diffuse Lymphoma | Neoplasms Central | Large Bcell
      KOL-Index: 9978

      Antiangiogenic therapy has shown clear activity and improved survival benefit for certain tumor types. However, an incomplete understanding of the mechanisms of action of antiangiogenic agents has hindered optimization and broader application of this new therapeutic modality. In particular, the impact of antiangiogenic therapy on tumor blood flow and oxygenation status (i.e., the role of vessel pruning versus normalization) remains controversial. This controversy has become critical as ...

      Known for Glioblastoma Patients | Improved Tumor | Antiangiogenic Therapy | Blood Perfusion | Survival Benefit

      Key People For Extracellular Vesicles

      Top KOLs in the world
      Clotilde Théry
      extracellular vesicles dendritic cells international society
      Graça Raposo
      extracellular vesicles dendritic cells early endosomes
      Jan O Lötvall
      extracellular vesicles allergic rhinitis bone marrow
      Edit Irén Buzás
      extracellular vesicles rheumatoid arthritis histidine decarboxylase
      Willem Stoorvogel
      dendritic cells extracellular vesicles plasma membrane
      Marca H M Wauben
      extracellular vesicles adjuvant arthritis dendritic cells

      Fred H Hochberg:Expert Impact

      Concepts for whichFred H Hochberghas direct influence:Extracellular vesicles,  Brain tumors,  Primary cns lymphoma,  Central nervous,  Malignant glioma,  Recurrent glioblastoma,  Glioblastoma multiforme,  Cranial irradiation.

      Fred H Hochberg:KOL impact

      Concepts related to the work of other authors for whichfor which Fred H Hochberg has influence:Extracellular vesicles,  Central nervous,  Brain metastases,  Breast cancer,  Stem cells,  Magnetic resonance,  Gene therapy.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Massachusetts General Hospital, Boston, Massachusetts, USA | Scintillon Institute, La Jolla, CA, United States. | University of California, San Diego, Department of Neurosurgery, La Jolla, CA, USA | Scintillon Institute, La Jolla, CA, USA | Scintillo

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.